Literature DB >> 11235987

Antioxidants inhibit TNFalpha-induced motility and invasion of human osteosarcoma cells: possible involvement of NFkappaB activation.

K Harimaya1, K Tanaka, Y Matsumoto, H Sato, S Matsuda, Y Iwamoto.   

Abstract

Osteosarcoma is the most frequent malignant bone tumor in children. It is highly invasive, however, the mechanisms behind osteosarcoma cell invasion are as yet still unknown. In the present study, treatment with TNFalpha enhanced the invasiveness of two human osteosarcoma cell lines, OST and MNNG. TNFalpha treatment also induced tumor cell motility, adhesion to laminin, the expression of matrix metalloproteinase 9 (MMP9), and the nuclear translocation of nuclear factor kappaB (NFkappaB) in the osteosarcoma cells. Moreover, antioxidants inhibited TNFalpha-induced osteosarcoma cell invasion, motility and NFkappaB nuclear translocation, but not adhesion to laminin or MMP9 expression. NFkappaB decoy, another NFkappaB inhibitor, also inhibited TNFalpha-induced osteosarcoma cell invasion and motility. Therefore, motility and NFkappaB activation were possibly related to TNFalpha-induced osteosarcoma cell invasion. However, adhesion to laminin or MMP did not demonstrate any correlation with TNFalpha-induced osteosarcoma cell invasion. Although NFkappaB is known to regulate TNFalpha-induced phenotypes, it may influence only motility and invasion, but not the MMP or laminin-mediated adhesion of these osteosarcoma cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11235987     DOI: 10.1023/a:1006791723233

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  61 in total

Review 1.  Pathology of chemotaxis and random mobility.

Authors:  M E Miller
Journal:  Semin Hematol       Date:  1975-01       Impact factor: 3.851

2.  Transformation of human cells in culture by N-methyl-N'-nitro-N-nitrosoguanidine.

Authors:  J S Rhim; D K Park; P Arnstein; R J Huebner; E K Weisburger; W A Nelson-Rees
Journal:  Nature       Date:  1975-08-28       Impact factor: 49.962

3.  Intracellular thiols regulate activation of nuclear factor kappa B and transcription of human immunodeficiency virus.

Authors:  F J Staal; M Roederer; L A Herzenberg; L A Herzenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

Review 4.  On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy.

Authors:  O S Bruland; A Pihl
Journal:  Eur J Cancer       Date:  1997-10       Impact factor: 9.162

5.  A proposal for the definition of terms related to locomotion of leucocytes and other cells.

Authors:  H U Keller; P C Wilkinson; M Abercrombie; E L Becker; J G Hirsch; M E Miller; W Scottramsey; S H Zigmond
Journal:  Clin Exp Immunol       Date:  1977-03       Impact factor: 4.330

6.  Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo.

Authors:  M Fràter-Schröder; W Risau; R Hallmann; P Gautschi; P Böhlen
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

Review 7.  Cancer metastasis. Organ colonization and the cell-surface properties of malignant cells.

Authors:  G L Nicolson
Journal:  Biochim Biophys Acta       Date:  1982-12-21

8.  Antiviral effects of recombinant tumour necrosis factor in vitro.

Authors:  J Mestan; W Digel; S Mittnacht; H Hillen; D Blohm; A Möller; H Jacobsen; H Kirchner
Journal:  Nature       Date:  1986 Oct 30-Nov 5       Impact factor: 49.962

9.  Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells.

Authors:  H Sato; M Seiki
Journal:  Oncogene       Date:  1993-02       Impact factor: 9.867

10.  An essential role for nuclear factor kappa B in preventing TNF-alpha-induced cell death in prostate cancer cells.

Authors:  M Sumitomo; M Tachibana; J Nakashima; M Murai; A Miyajima; F Kimura; M Hayakawa; H Nakamura
Journal:  J Urol       Date:  1999-02       Impact factor: 7.450

View more
  7 in total

1.  Oxidative stress induced by low-dose doxorubicin promotes the invasiveness of osteosarcoma cell line U2OS in vitro.

Authors:  Seung Han Shin; Young Joon Choi; Hyewon Lee; Han-Soo Kim; Sung Wook Seo
Journal:  Tumour Biol       Date:  2015-08-23

2.  Effect of cytotoxic T-lymphocyte antigen-4, TNF-alpha polymorphisms on osteosarcoma: evidences from a meta-analysis.

Authors:  Jianwei Liu; Junli Wang; Weiping Jiang; Yujin Tang
Journal:  Chin J Cancer Res       Date:  2013-12       Impact factor: 5.087

3.  Basic fibroblast growth factor in the bone microenvironment enhances cell motility and invasion of Ewing's sarcoma family of tumours by activating the FGFR1-PI3K-Rac1 pathway.

Authors:  S Kamura; Y Matsumoto; J-I Fukushi; T Fujiwara; K Iida; Y Okada; Y Iwamoto
Journal:  Br J Cancer       Date:  2010-07-06       Impact factor: 7.640

4.  Role of the VEGF-Flt-1-FAK pathway in the pathogenesis of osteoclastic bone destruction of giant cell tumors of bone.

Authors:  Yoshihiro Matsumoto; Yuko Okada; Jun-Ichi Fukushi; Satoshi Kamura; Toshifumi Fujiwara; Keiichiro Iida; Mihoko Koga; Shuichi Matsuda; Katsumi Harimaya; Akio Sakamoto; Yukihide Iwamoto
Journal:  J Orthop Surg Res       Date:  2010-11-09       Impact factor: 2.359

5.  Tumour-associated macrophages correlate with poor prognosis in myxoid liposarcoma and promote cell motility and invasion via the HB-EGF-EGFR-PI3K/Akt pathways.

Authors:  A Nabeshima; Y Matsumoto; J Fukushi; K Iura; T Matsunobu; M Endo; T Fujiwara; K Iida; Y Fujiwara; M Hatano; N Yokoyama; S Fukushima; Y Oda; Y Iwamoto
Journal:  Br J Cancer       Date:  2015-01-06       Impact factor: 7.640

6.  Small GTP-binding protein, Rho, both increased and decreased cellular motility, activation of matrix metalloproteinase 2 and invasion of human osteosarcoma cells.

Authors:  Y Matsumoto; K Tanaka; K Harimaya; F Nakatani; S Matsuda; Y Iwamoto
Journal:  Jpn J Cancer Res       Date:  2001-04

7.  Tannin extracted from Sumac inhibits vascular smooth muscle cell migration.

Authors:  Hanieh Zargham; Ramin Zargham
Journal:  Mcgill J Med       Date:  2008-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.